Fig. 6
From: Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
Anti-tumor activity of an LC53-0110 analog combined with an immunomodulatory drug. a The cytotoxic effects of 5 nM of LC53-0151 or 2 μM of pomalidomide alone or together on MM.1S cells were determined by MTT assay. b LC53-0151 or pomalidomide alone or together in mice bearing MM.1S xenografts as indicated. The mean tumor volume for each animal in the vehicle and treatment groups was determined during the study. c The mean tumor weight for each animal in the vehicle and treatment groups was determined at the end of the study. Data points, mean+/−SE (n = 8)